Deep Dive: Regulatory Status of Popular Compounded Peptides Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) FDA FDA releases denial letters for unapproved drugs, a step toward transparency